BSE: 531569 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sanjivani Paranteral Ltd is a average quality company.
The key valuation ratios of Sanjivani Paranteral Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sanjivani Paranteral Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 5.7% | -7.3% | -33% | -227.3% | 0% | -266% | 266.4% | 0% | 0% | 55.3% | - |
| Value Creation Index ⓘ | -0.6 | -1.5 | NA | NA | NA | NA | 18.0 | NA | NA | 3.0 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 133 | 115 | 32.7 | 18 | 25.1 | 16.4 | 25.1 | 30.6 | 35.5 | 54.4 | 62 |
| Sales YoY Gr. | - | -13.2% | -71.7% | -45% | 39.7% | -34.8% | 53.4% | 22% | 15.9% | 53.3% | - |
| Adj EPS ⓘ | -4.2 | -25.2 | -46 | -90 | -3.7 | -3.2 | 1.5 | 4.7 | 4.2 | 5 | 5.8 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | 214.8% | -10.9% | 20.3% | - |
| BVPS (₹) ⓘ | 54.5 | 29.7 | -14.8 | -89.6 | -80 | -82.9 | -52.8 | -7.6 | -3.1 | 22.1 | 27 |
| Adj Net Profit ⓘ | -2.5 | -14.9 | -27.2 | -53.1 | -2.2 | -1.9 | 1.3 | 4.7 | 4.2 | 5.9 | 7 |
| Cash Flow from Ops. ⓘ | -1.2 | 0.5 | 9.6 | 3.1 | 2.5 | -0.2 | 0.6 | 8.5 | 4.7 | -10.7 | - |
| Debt/CF from Ops. ⓘ | -47.6 | 139.7 | 6.3 | 15.8 | 19.4 | -280.1 | 79 | 0.7 | 0.5 | -0.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -9.5% | 16.7% | 29.4% | 53.3% | ||||
| Adj EPS ⓘ | NA | NA | 50% | 20.3% | ||||
| BVPSⓘ | -9.5% | NA | NA | NA | ||||
| Share Price | 32.2% | 101.7% | 118.4% | 111% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -7.4 | -60 | -618.2 | 172.5 | 4.4 | 3.9 | -2.7 | -17.9 | -78.4 | 47.3 | 23.7 |
| Op. Profit Mgn % ⓘ | 4 | -4.8 | -70.4 | -289.8 | -7 | -3.4 | 8.5 | 13.9 | 14.8 | 14.7 | 14.9 |
| Net Profit Mgn % ⓘ | -1.9 | -12.9 | -83.1 | -295.5 | -8.7 | -11.3 | 5.1 | 15.3 | 11.8 | 10.8 | 11.1 |
| Debt to Equity ⓘ | 1.8 | 3.6 | -6.9 | -0.9 | -1 | -1 | -1 | -0.8 | -0.8 | 0 | 0.2 |
| Working Cap Days ⓘ | 263 | 284 | 722 | 649 | 171 | 179 | 133 | 128 | 121 | 118 | 93 |
| Cash Conv. Cycle ⓘ | 197 | 221 | 567 | 420 | -105 | -169 | -112 | -90 | -82 | -3 | 57 |
Return on Equity has increased versus last 3 years average to 23.70%
Sales growth is growing at healthy rate in last 3 years 29.42%
Net Profit is growing at healthy rate in last 3 years 50.01%
Sales growth is good in last 4 quarters at 45.65%
No data to display
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 5.8 | - |
| TTM Sales (₹ Cr.) | 62.4 | - |
| BVPS (₹.) ⓘ | 27 | - |
| Reserves (₹ Cr.) ⓘ | 20 | - |
| P/BV ⓘ | 10.82 | - |
| PE ⓘ | 50.23 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 122.15 / 360.60 |
| All Time Low / High (₹) | 1.76 / 360.60 |
| Market Cap (₹ Cr.) | 348 |
| Equity (₹ Cr.) | 11.9 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.7 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 133 | 115 | 33 | 18 | 25 | 16 | 25 | 31 | 35 | 54 |
| Operating Expenses ⓘ | 128 | 121 | 56 | 70 | 27 | 17 | 23 | 26 | 30 | 46 |
| Manufacturing Costs | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 3 | 3 | 4 |
| Material Costs | 120 | 113 | 28 | 25 | 15 | 9 | 15 | 12 | 19 | 28 |
| Employee Cost | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 4 |
| Other Costs ⓘ | 3 | 4 | 23 | 40 | 8 | 4 | 4 | 8 | 5 | 10 |
| Operating Profit ⓘ | 5 | -6 | -23 | -52 | -2 | -1 | 2 | 4 | 5 | 8 |
| Operating Profit Margin (%) | 4.0% | -4.8% | -71.2% | -290.0% | -7.0% | -3.4% | 8.5% | 13.9% | 14.8% | 14.7% |
| Other Income ⓘ | 1 | 1 | 3 | 0 | 1 | 0 | 0 | 2 | 1 | 1 |
| Interest ⓘ | 8 | 9 | 5 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -3 | -15 | -26 | -53 | -2 | -2 | 1 | 5 | 5 | 8 |
| Tax ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit After Tax | -2 | -15 | -26 | -53 | -2 | -2 | 1 | 5 | 5 | 6 |
| PAT Margin (%) | -1.8% | -12.7% | -80.3% | -295.0% | -8.2% | -10.4% | 5.7% | 15.8% | 12.7% | 11.3% |
| Adjusted EPS (₹) | -4.1 | -24.8 | -44.5 | -90.0 | -3.5 | -2.9 | 1.7 | 4.9 | 4.5 | 5.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 32 | 18 | -9 | -53 | -47 | -49 | -45 | -8 | -3 | 26 |
| Share Capital ⓘ | 6 | 6 | 6 | 6 | 6 | 6 | 8 | 10 | 10 | 12 |
| Reserves ⓘ | 26 | 12 | -15 | -59 | -53 | -55 | -53 | -18 | -13 | 14 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 55 | 61 | 57 | 45 | 45 | 45 | 42 | 3 | 1 | 1 |
| Long Term Debt | 5 | 12 | 7 | 4 | 8 | 8 | 5 | 3 | 1 | 1 |
| Short Term Debt | 50 | 49 | 50 | 41 | 37 | 37 | 37 | 0 | 0 | 0 |
| Trade Payables | 12 | 6 | 3 | 12 | 12 | 11 | 11 | 11 | 14 | 6 |
| Others Liabilities ⓘ | 14 | 9 | 8 | 21 | 8 | 9 | 12 | 12 | 10 | 11 |
| Total Liabilities ⓘ | 114 | 93 | 60 | 25 | 18 | 16 | 19 | 18 | 21 | 43 |
Fixed Assets | ||||||||||
| Gross Block | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 23 | 24 | 27 |
| Accumulated Depreciation | 8 | 9 | 11 | 12 | 13 | 14 | 14 | 15 | 16 | 17 |
| Net Fixed Assetsⓘ | 14 | 13 | 11 | 10 | 9 | 8 | 8 | 7 | 8 | 10 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 23 | 20 | 10 | 2 | 1 | 2 | 1 | 2 | 5 | 10 |
| Trade Receivables | 67 | 48 | 32 | 5 | 5 | 1 | 7 | 5 | 2 | 5 |
| Cash Equivalents | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| Others Assetsⓘ | 10 | 12 | 7 | 7 | 3 | 5 | 4 | 4 | 6 | 9 |
| Total Assets ⓘ | 114 | 93 | 60 | 25 | 18 | 16 | 19 | 18 | 21 | 43 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -1 | 0 | 10 | 3 | 2 | 0 | 1 | 9 | 5 | -11 |
| PBT ⓘ | -3 | -15 | -17 | -53 | -2 | -2 | 1 | 5 | 5 | 8 |
| Adjustment ⓘ | 8 | 9 | 6 | 2 | 1 | 2 | 1 | -1 | 1 | 1 |
| Changes in Working Capital ⓘ | -7 | 6 | 21 | 55 | 3 | 0 | -2 | 4 | -1 | -18 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Cash Flow From Investing Activity ⓘ | 9 | -1 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -12 |
| Capex | 9 | -1 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -3 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | -7 | -1 | -10 | -3 | -2 | 0 | 0 | -8 | -4 | 23 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 25 |
| Net Proceeds from Borrowing ⓘ | -1 | 8 | -5 | -3 | 4 | 1 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | -8 | -8 | -5 | 0 | 0 | -1 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 1 | 0 | 0 | 0 | -6 | 0 | -3 | -9 | -3 | -2 |
| Net Cash Flow ⓘ | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -7.19 | -58.98 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 54.08 |
| ROCE (%) | 5.69 | -7.28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 55.32 |
| Asset Turnover Ratio | 1.15 | 1.12 | 0.43 | 0.42 | 1.17 | 0.97 | 1.47 | 1.66 | 1.81 | 1.77 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | N/A | N/A | 1 | 1.8 | 1 | -1.83 | Working Capital Days |
| Receivable Days | 181 | 182 | 446 | 378 | 76 | 70 | 55 | 68 | 35 | 21 |
| Inventory Days | 60 | 68 | 168 | 124 | 21 | 25 | 18 | 16 | 36 | 48 |
| Payable Days | 47 | 30 | 60 | 108 | 289 | 461 | 264 | 327 | 247 | 125 |
Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company’s products includes oral solids, small volume parenterals and sterile powder formulations.
The company has grown many folds and aspires to be a respected research-based company. With its diverse product portfolio, it is rapidly expanding its reach to the global marketplace, riding on its success in India and in the world’s emerging and developed markets.
After establishing itself in India, Sanjivani has extended its reach globally by entering the markets of Asia, Europe, Africa and Latin America. The company has active presence in countries like Russia, Ukraine, Uzbekistan, Turkmenistan, Fiji, Vietnam, Sri Lanka, Nepal, Malaysia, Thailand, Nigeria and Peru, to name a few. Sanjivani Parenteral has also got its plant approved by the registration authorities of Congo, Sudan and Sri Lanka. It is making its presence felt in the world market now, through leveraging its manufacturing capacity, quality of products and international alliances.
International business contributes about 30% of the company’s revenue and is set to grow to more than 50% in the coming two years. This includes the sales of Sanjivani’s own brands and the revenue from the contract manufacturing services that the company provides to its overseas clients. The company is in the making of a strong base to broaden its horizons.
Sanjivani has been a regular supplier to the armed forces’ hospitals in India. Furthermore, many government and private hospitals have availed of the products and services offered by Sanjivani across the country. The company also has its own marketing operations in India and boasts of over 1000 distributors all over India.
Products
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Inatant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
